ConforMIS, Orthofix and OrthoPediatrics Report Preliminary 4Q18 and FY 2018 Results

Preliminary results for ConforMIS, Orthofix and OrthoPediatrics were mixed. While ConforMI's net revenue for the year grew in the double digits, adjusting for product-only revenue reveals a mostly flat year. Orthofix rode strong spinal implant sales to mid-single-digit growth for the year but was impacted by the slowdown in the biologics market. OrthoPediatrics continued to leverage its leadership position in the pediatric space to achieve aggressive sales growth for both the quarter and year.